• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.110 -0.250 (-4.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 01, 2026
From Immuneering Corporation
Via GlobeNewswire
Friday's session: gap up and gap down stocks ↗
May 22, 2026
Via Chartmill
News headline image
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
From Immuneering Corporation
Via GlobeNewswire
IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
January 07, 2026
Via Stocktwits
News headline image
Earnings Scheduled For November 12, 2025 ↗
November 12, 2025
 
Via Benzinga
News headline image
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
April 20, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
April 06, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
March 17, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 06, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Leerink Global Healthcare Conference
March 02, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
From Immuneering Corporation
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
January 08, 2026
Via Chartmill
These stocks are gapping in today's session ↗
January 08, 2026
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
January 08, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
January 07, 2026
Via Chartmill
News headline image
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
January 07, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
December 23, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
December 17, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
December 16, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
Immuneering (IMRX) Q3 2025 Earnings Transcript ↗
November 13, 2025
Immuneering (IMRX) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
November 12, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
A Preview Of Immuneering's Earnings ↗
November 11, 2025
 
Via Benzinga
News headline image
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
November 04, 2025
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap